A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November 2009 issue of the journal “Nature Medicine”[the number 1 journal in General Medicine with an I.F of 28.054] by Prof. Thistlethwaite PA, Li X and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-491-5p inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3
Significance:
Given that: (1) one billion people have hypertension every year worldwide; (2) 0.66 billion people have hypertension from developing countries every year worldwide; (4) hypertension is one of the top 10 causes of death worldwide; and (4) 9.4 million people worldwide die of complications of hypertension every year worldwide, there is an urgent need to find: (i) a side-effect-free drug; and (ii) a way to effectively treat and cure high blood pressure.
This study suggests, for the first time, that MiRNA-491-5p, by decreasing the expression of its target gene Notch3, it may lower blood pressure. Thus, pharmacological formulations encompassing “MiRNA-491-5p activators” may be used to treat pulmonary arterial hypertension.
Undisclosed information: How MiRNA-491-5p inhibits the development of pulmonary arterial hypertension
Amount: $100
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
To cite: Boominathan, Small RNA-based therapy for pulmonary arterial hypertension: MiRNA-491-5p inhibits the development of pulmonary arterial hypertension via down regulation of its target gene Notch3, 7/August/2016, 2.58 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org